Abstract
It is well known, that the pharmaceutical industry is struggling with increasing cost and length of R&D projects. Earnings of a drug drop drastically after patent expiration. Thus, the industry spends much effort on reducing Time-to-Market. In the literature, little attention is given to drug launching activities after the drug has been approved. In this paper, we present a recourse-based stochastic model, which allows for time phasing the market entries to balance the fluctuating demand with the fixed and periodic production of the active pharmaceutical ingredient. The two major risk elements during launch are forecasting inaccuracy and the risk of a required label change from local regulatory authorities. Robust solutions are found by implementing the Robust Optimization framework.
| Original language | English |
|---|---|
| Pages (from-to) | 935-939 |
| Number of pages | 5 |
| Journal | Computer Aided Chemical Engineering |
| Volume | 29 |
| DOIs | |
| State | Published - 2011 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 9 Industry, Innovation, and Infrastructure
Keywords
- Market launch planning
- Multi-echelon pharmaceutical supply chain
- Recourse-based stochastic programming
- Robustness optimization
Fingerprint
Dive into the research topics of 'Robust Market Launch Planning for a Multi-Echelon Pharmaceutical Supply Chain'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver